30 Sep 2015

The PATH Malaria Vaccine Initiative (MVI) is collaborating with the Seattle Biomedical Research Institute (Seattle BioMed) to establish a center devoted to testing the safety and efficacy of malaria vaccine candidates in humans. The new Malaria Clinical Trials Center (MCTC) at Seattle BioMed will be one of only a handful of facilities of its kind worldwide and will help meet the growing demand to test new interventions against the deadly malaria parasite.

MVI is providing technical and financial support for the development of the MCTC as part of its efforts to accelerate the assessment of malaria vaccine candidates and thereby ensure that only the most promising candidates advance to field trials.